BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 11289126)

  • 1. Vascular endothelial growth factor and basic fibroblast growth factor urine levels as predictors of outcome in hormone-refractory prostate cancer patients: a cancer and leukemia group B study.
    Bok RA; Halabi S; Fei DT; Rodriquez CR; Hayes DF; Vogelzang NJ; Kantoff P; Shuman MA; Small EJ
    Cancer Res; 2001 Mar; 61(6):2533-6. PubMed ID: 11289126
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic significance of plasma vascular endothelial growth factor levels in patients with hormone-refractory prostate cancer treated on Cancer and Leukemia Group B 9480.
    George DJ; Halabi S; Shepard TF; Vogelzang NJ; Hayes DF; Small EJ; Kantoff PW;
    Clin Cancer Res; 2001 Jul; 7(7):1932-6. PubMed ID: 11448906
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Are basic fibroblast growth factor and vascular endothelial growth factor prognostic indicators in pediatric patients with malignant solid tumors?
    Tabone MD; Landman-Parker J; Arcil B; Coudert MC; Gerota I; Benbunan M; Leverger G; Dosquet C
    Clin Cancer Res; 2001 Mar; 7(3):538-43. PubMed ID: 11297245
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Are angiogenic factors, cytokines, and soluble adhesion molecules prognostic factors in patients with renal cell carcinoma?
    Dosquet C; Coudert MC; Lepage E; Cabane J; Richard F
    Clin Cancer Res; 1997 Dec; 3(12 Pt 1):2451-8. PubMed ID: 9815646
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase II study of razoxane, an antiangiogenic topoisomerase II inhibitor, in renal cell cancer with assessment of potential surrogate markers of angiogenesis.
    Braybrooke JP; O'Byrne KJ; Propper DJ; Blann A; Saunders M; Dobbs N; Han C; Woodhull J; Mitchell K; Crew J; Smith K; Stephens R; Ganesan TS; Talbot DC; Harris AL
    Clin Cancer Res; 2000 Dec; 6(12):4697-704. PubMed ID: 11156222
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High tumor levels of vascular endothelial growth factor predict poor response to systemic therapy in advanced breast cancer.
    Foekens JA; Peters HA; Grebenchtchikov N; Look MP; Meijer-van Gelder ME; Geurts-Moespot A; van der Kwast TH; Sweep CG; Klijn JG
    Cancer Res; 2001 Jul; 61(14):5407-14. PubMed ID: 11454684
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Plasma vascular endothelial growth factor levels have prognostic significance in patients with acute myeloid leukemia but not in patients with myelodysplastic syndromes.
    Aguayo A; Kantarjian HM; Estey EH; Giles FJ; Verstovsek S; Manshouri T; Gidel C; O'Brien S; Keating MJ; Albitar M
    Cancer; 2002 Nov; 95(9):1923-30. PubMed ID: 12404286
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Basic fibroblast growth factor (bFGF) and vascular endothelial growth factor (VEGF) levels, as prognostic indicators in NSCLC.
    Iwasaki A; Kuwahara M; Yoshinaga Y; Shirakusa T
    Eur J Cardiothorac Surg; 2004 Mar; 25(3):443-8. PubMed ID: 15019676
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Urinary vascular endothelial growth factor and its correlation with bladder cancer recurrence rates.
    Crew JP; O'Brien T; Bicknell R; Fuggle S; Cranston D; Harris AL
    J Urol; 1999 Mar; 161(3):799-804. PubMed ID: 10022687
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High plasma basic fibroblast growth factor concentration is associated with response to thalidomide in progressive multiple myeloma.
    Neben K; Moehler T; Egerer G; Kraemer A; Hillengass J; Benner A; Ho AD; Goldschmidt H
    Clin Cancer Res; 2001 Sep; 7(9):2675-81. PubMed ID: 11555579
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Basic fibroblast growth factor and vascular endothelial growth factor in sera from non-small cell lung cancer patients.
    Brattström D; Bergqvist M; Larsson A; Holmertz J; Hesselius P; Rosenberg L; Brodin O; Wagenius G
    Anticancer Res; 1998; 18(2A):1123-7. PubMed ID: 9615776
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Basic fibroblast growth factor (bFGF) and vascular endothelial growth factor (VEGF) are elevated in peripheral blood plasma of patients with chronic lymphocytic leukemia and decrease after intensive fludarabine-based treatment].
    Smolej L; Andrýs C; Krejsek J; Belada DZ; Zák P; Siroký O; Malý J
    Vnitr Lek; 2007 Nov; 53(11):1171-6. PubMed ID: 18277626
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vascular endothelial growth factor levels in ovarian cyst fluid correlate with malignancy.
    Hazelton D; Nicosia RF; Nicosia SV
    Clin Cancer Res; 1999 Apr; 5(4):823-9. PubMed ID: 10213218
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Correlation of vascular endothelial growth factor expression with fibroblast growth factor-8 expression and clinico-pathologic parameters in human prostate cancer.
    West AF; O'Donnell M; Charlton RG; Neal DE; Leung HY
    Br J Cancer; 2001 Aug; 85(4):576-83. PubMed ID: 11506499
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Plasma vascular endothelial growth factor is useful in assessing progression of breast cancer post surgery and during adjuvant treatment.
    Wu Y; Saldana L; Chillar R; Vadgama JV
    Int J Oncol; 2002 Mar; 20(3):509-16. PubMed ID: 11836562
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pre-operative serum vascular endothelial growth factor can select patients for adjuvant treatment after curative resection in colorectal cancer.
    Chin KF; Greenman J; Gardiner E; Kumar H; Topping K; Monson J
    Br J Cancer; 2000 Dec; 83(11):1425-31. PubMed ID: 11076648
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic significance of plasma chromogranin a levels in patients with hormone-refractory prostate cancer treated in Cancer and Leukemia Group B 9480 study.
    Taplin ME; George DJ; Halabi S; Sanford B; Febbo PG; Hennessy KT; Mihos CG; Vogelzang NJ; Small EJ; Kantoff PW
    Urology; 2005 Aug; 66(2):386-91. PubMed ID: 16098367
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High serum levels of vascular endothelial growth factor predict poor response to transarterial chemoembolization in hepatocellular carcinoma: a prospective study.
    Poon RT; Lau C; Yu WC; Fan ST; Wong J
    Oncol Rep; 2004 May; 11(5):1077-84. PubMed ID: 15069550
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The prognostic significance of plasma interleukin-6 levels in patients with metastatic hormone-refractory prostate cancer: results from cancer and leukemia group B 9480.
    George DJ; Halabi S; Shepard TF; Sanford B; Vogelzang NJ; Small EJ; Kantoff PW
    Clin Cancer Res; 2005 Mar; 11(5):1815-20. PubMed ID: 15756004
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Independent expression of serum vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF) in patients with carcinoma and sarcoma.
    Linder C; Linder S; Munck-Wikland E; Strander H
    Anticancer Res; 1998; 18(3B):2063-8. PubMed ID: 9677468
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.